Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ERS 2025

European Respiratory Society (ERS) – 35th Annual Congress

September 27 - October 1, 2025

    1. All
    2. FASENRA (benralizumab)
    3. Respiratory Unbranded
    4. TEZSPIRE (tezepelumab)
    5. BREZTRI/TRIXEO
    6. NOVELTY
    7. Tozorakimab

    PDF

    Changes in airway structure/function with benralizumab treatment of severe eosinophilic asthma (SEA) observed with Functional Respiratory Imaging (FRI)

    PDF

    Predicting long-term remission with benralizumab in severe eosinophilic asthma (SEA): Post-hoc analysis of SIROCCO, CALIMA, BORA

    PDF

    Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2

    PDF

    Effects of benralizumab on serum biomarkers and biomarker response after shifting from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA)

    PDF

    Whole blood transcriptomic profile effects of benralizumab or mepolizumab in eosinophilic granulomatosis with polyangiitis

    PDF

    Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following 2 years of treatment with anti-IL-5/R therapies

    PDF

    EGPA disease burden in Europe and US: evidence from real-world clinical practice

    PDF

    Healthcare resource utilization (HCRU) and costs in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective observational cohort study in England

    PDF

    Airway IL-33 levels are similar in current and former smokers with stable or exacerbating COPD

    PDF

    Predictors of recovery in US patients hospitalized for viral lower respiratory tract disease: an analysis of linked electronic health records and claims data

    PDF

    Real-world study on causes of death in people with Chronic Obstructive Pulmonary Disease (COPD) in England

    PDF

    Risk factors for mortality and IMV/ECMO in US patients hospitalized for viral LRTD

    PDF

    Real-world occurrence of cardiopulmonary events among patients with COPD: the ABACOS-OUTCOMES Study (US)

    PDF

    Early and continued improvements in asthma control in patients with severe, uncontrolled asthma after tezepelumab initiation: real-world ASCENT study

    PDF

    Bronchoscopy measurements of tezepelumab pharmacokinetics and TSLP in asthmatic patients

    PDF

    OCS reduction with tezepelumab in OCS-dependent patients with severe allergic, eosinophilic asthma in WAYFINDER

    PDF

    On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER

    PDF

    Efficacy of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps and comorbid NSAID-exacerbated respiratory disease (WAYPOINT)

    PDF

    Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: results from the phase 3 WAYPOINT study

    PDF

    Utility of CompEx as a component of clinical remission in NAVIGATOR

    PDF

    Reduced mortality and cardiopulmonary risk for patients with COPD and asthma when initiating single inhaler triple therapy compared to multiple inhaler triple therapy (MITT): MAZI Asthma Study

    PDF

    Burden, characteristics and outcomes of COPD patients experiencing moderate or severe exacerbations on triple therapy (ANTLIA NOVELTY)

    PDF

    Tozorakimab exerts unique dual pharmacology to reduce COPD epithelial remodelling [poster]

    PDF

    Tozorakimab exerts unique dual pharmacology to reduce COPD epithelial remodelling [Oral presentation]

    PDF

    Changes in airway structure/function with benralizumab treatment of severe eosinophilic asthma (SEA) observed with Functional Respiratory Imaging (FRI)

    PDF

    Predicting long-term remission with benralizumab in severe eosinophilic asthma (SEA): Post-hoc analysis of SIROCCO, CALIMA, BORA

    PDF

    Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2

    PDF

    Effects of benralizumab on serum biomarkers and biomarker response after shifting from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA)

    PDF

    Whole blood transcriptomic profile effects of benralizumab or mepolizumab in eosinophilic granulomatosis with polyangiitis

    PDF

    Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following 2 years of treatment with anti-IL-5/R therapies

    PDF

    EGPA disease burden in Europe and US: evidence from real-world clinical practice

    PDF

    Healthcare resource utilization (HCRU) and costs in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective observational cohort study in England

    PDF

    Airway IL-33 levels are similar in current and former smokers with stable or exacerbating COPD

    PDF

    Predictors of recovery in US patients hospitalized for viral lower respiratory tract disease: an analysis of linked electronic health records and claims data

    PDF

    Real-world study on causes of death in people with Chronic Obstructive Pulmonary Disease (COPD) in England

    PDF

    Risk factors for mortality and IMV/ECMO in US patients hospitalized for viral LRTD

    PDF

    Real-world occurrence of cardiopulmonary events among patients with COPD: the ABACOS-OUTCOMES Study (US)

    PDF

    Early and continued improvements in asthma control in patients with severe, uncontrolled asthma after tezepelumab initiation: real-world ASCENT study

    PDF

    Bronchoscopy measurements of tezepelumab pharmacokinetics and TSLP in asthmatic patients

    PDF

    OCS reduction with tezepelumab in OCS-dependent patients with severe allergic, eosinophilic asthma in WAYFINDER

    PDF

    On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER

    PDF

    Efficacy of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps and comorbid NSAID-exacerbated respiratory disease (WAYPOINT)

    PDF

    Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: results from the phase 3 WAYPOINT study

    PDF

    Utility of CompEx as a component of clinical remission in NAVIGATOR

    PDF

    Reduced mortality and cardiopulmonary risk for patients with COPD and asthma when initiating single inhaler triple therapy compared to multiple inhaler triple therapy (MITT): MAZI Asthma Study

    PDF

    Burden, characteristics and outcomes of COPD patients experiencing moderate or severe exacerbations on triple therapy (ANTLIA NOVELTY)

    PDF

    Tozorakimab exerts unique dual pharmacology to reduce COPD epithelial remodelling [poster]

    PDF

    Tozorakimab exerts unique dual pharmacology to reduce COPD epithelial remodelling [Oral presentation]

    Disclaimer

    Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

    Connessiallasalute.it

    This site is intended for healthcare professionals practicing in the US.
    ©2026 AstraZeneca. All rights reserved.

    US-107328
    Last Updated 5/26

    Contact Us

    About Us

    AstraZeneca-US.com

    Grant Opportunities  

    Survey Feedback

    Your Privacy Choice

    Consumer Health Data
    Privacy Notice

    Privacy Notice | Legal Notice | Cookie Preferences

    Welcome to AstraZeneca Medical Information

    The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

     

    This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

     

    Are you a healthcare professional practicing in the United States?

    I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
    This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
    I am not a healthcare professional practicing in the United States